Bio-Techne partners with BenchSci to enhance its available publication data of its commercial antibodies

Novus Biologicals and R&D Systems announce that they will list their catalog of antibodies on BenchSci’s website to increase the amount of published antibody validation data available to researchers. BenchSci is a revolutionary data mining company that uses artificial intelligence and machine learning to gather published antibody usage data from open- and closed-access journals about commercial antibodies available for purchase on their website.


Antibodies that lack specificity or perform poorly in certain applications produce unreliable data that cannot be reproduced which results in wasted time, wasted resources, and, most importantly, a delay in the publication of critical research results. Up until now, researchers often had to spend a significant amount of time doing their own product research on antibodies they planned on purchasing to ensure they would work as intended in their experiments. Using BenchSci, researchers can now quickly and easily make informed purchasing decisions on products based on their use in successful, unbiased publications.

“The BenchSci platform is a real scientific game changer,” says Karen Padgett, Founder of Novus Biologicals and current VP of the Global Marketing and Antibody Business Unit. “It allows scientists to match their research with published data on validated antibodies. With the Bio-Techne brands of R&D Systems and Novus Biologicals now on the BenchSci platform we can help scientists find the exact antibody they need.”

Liran Belenzon, CEO of BenchSci, adds “We’re thrilled to add Novus products to our platform, increasing their discoverability by researchers in more than 1,300 academic institutions and 14 top pharmaceutical companies worldwide. BenchSci already helps researchers find the right antibodies up to 24x faster. With this partnership, we can also help them purchase those antibodies faster, further increasing research efficiency to drive more rapid discoveries.”

Innovative technology like this will undoubtedly reduce the time, money and uncertainty involved in the planning of materials and methods for experiments, allowing researchers to spend more time doing the research that interests them and less time finding the reagents to do it.

BenchSci: BenchSci is decoding the world’s biological data to reduce the time, uncertainty, and cost of biomedical research. Researchers waste time and money on antibodies that don't work. This slows studies, destroys samples, and leaves patients waiting for treatments. Artificial intelligence can solve the problem, and we're building it. Our technology helps researchers find reliable antibodies 24x faster and 75% cheaper. We use machine learning to decode comprehensive open- and closed-access datasets, display published figures with no commercial bias, and allow researchers to search by important experimental variables. BenchSci now powers discoveries in 14 of the top 20 pharmaceutical companies and 1,300 academic institutions. Academic researchers can sign up free at Industry researchers can request a demo at Passionate people can join us at

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota. The Protein Platforms Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means to develop accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $643 million in net sales in fiscal 2018 and has over 2,100 employees worldwide. For more information on Bio-Techne and its brands, please visit

Contact: Bryan Tinsley, Marketing Director, Novus Biologicals, 1 (303) 730-1950 x5814,

Release Date: 
Monday, October 1, 2018 - 12:00